Article
Pharmacology & Pharmacy
Lucja Kudla, Ryszard Bugno, Sabina Podlewska, Lukasz Szumiec, Lucja Wiktorowska, Andrzej J. Bojarski, Ryszard Przewlocki
Summary: This study evaluated the effects of G protein-biased opioid agonists SR-14968 and SR-17018 on antinociception, motor activity, and addiction-like behaviors in mice. The results showed that these compounds have strong antinociceptive effects, induce locomotor activity and addictive behaviors, and develop antinociceptive tolerance. Furthermore, SR agonists can slow down the development of antinociceptive tolerance to morphine and inhibit morphine withdrawal symptoms.
Review
Biochemistry & Molecular Biology
Zoe Li, Jie Liu, Fan Dong, Nancy Chang, Ruili Huang, Menghang Xia, Tucker A. Patterson, Huixiao Hong
Summary: The United States is facing a severe opioid crisis, with increasing numbers of deaths caused by both prescription and illegal opioids over the past two decades. Opioids are important for pain treatment but also highly addictive, making it difficult to combat this public health issue.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Leah M. Salinsky, Christina R. Merritt, Joshua C. Zamora, Juliana L. Giacomini, Noelle C. Anastasio, Kathryn A. Cunningham
Summary: Opioid misuse and overdose deaths are a significant public health problem involving the misuse of prescription opioids and potent fentanyl derivatives. Utilizing 5-HT2AR agonists as therapeutics for OUD presents opportunities and challenges.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Haoqing Wang, Florian Hetzer, Weijiao Huang, Qianhui Qu, Justin Meyerowitz, Jonas Kaindl, Harald Huebner, Georgios Skiniotis, Brian K. Kobilka, Peter Gmeiner
Summary: This study reported the structure of the mu-opioid receptor agonist PZM21 bound to mu OR in complex with G(i) protein, and its derivative FH210 with extremely low efficacy for arrestin recruitment. The study revealed a potential mechanism to reduce beta-arrestin recruitment by mu OR, holding promise for developing next-generation analgesics with fewer adverse effects.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2022)
Article
Biochemistry & Molecular Biology
Mengkang Gao, Yang Zhang, Bingxin Wang, Ning Guo, Lulian Shao, Weibin Zhai, Lei Jiang, Qiang Wang, Hai Qian, Lin Yan
Summary: Currently, it is challenging to develop effective analgesic drugs with minimal side effects. Multi-target drug treatments have shown higher efficacy and fewer side effects compared to single-target drug therapies. In this study, novel MOR/TRPV1 dual active ligands were designed and synthesized, demonstrating the potential for simultaneous targeting of both MOR and TRPV1 with a single molecule in order to discover new analgesic treatments.
BIOORGANIC CHEMISTRY
(2023)
Article
Neurosciences
Feng Du, Guangjuan Yin, Lei Han, Xi Liu, Dong Dong, Kaifang Duan, Jiantao Huo, Yanyan Sun, Longzhen Cheng
Summary: Chronic use of opioids is associated with opioid-induced hypersensitivity (OIH) and analgesic tolerance. In this study, researchers found that the loss of peripheral mu-opioid receptors (MORs) did not affect morphine-induced mechanical allodynia and anti-allodynic tolerance, suggesting that the peripheral MOR signaling pathway may not be an optimal target for preventing mechanical OIH and analgesic tolerance. Future studies should focus more on central mechanisms.
NEUROSCIENCE BULLETIN
(2023)
Article
Chemistry, Medicinal
Yifei Yang, Yonghai Wang, Aixia Zuo, Chunmei Li, Wenyan Wang, Wanglin Jiang, Xiaochen Zhang, Xin Che, Yang Zhang, Wentao Wu, Xiaobo Cen, Hongbo Wang, Jingwei Tian
Summary: Biased agonism refers to compounds' ability to preferentially activate certain signaling pathways and avoid adverse signaling pathways in a ligand-dependent manner for some G-protein-coupled receptors. In this study, a series of derivatives with potent highly biased MOR agonism were rationally designed and synthesized through modification and structure-activity relationship study of TRV130. The novel molecule LPM3480392 demonstrated improved in vitro biased agonism, good brain penetration, and produced potent antinociceptive effect with reduced respiratory suppression compared to TRV130.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Neurosciences
Shanna Babalonis, Sandra D. Comer, Jermaine D. Jones, Paul Nuzzo, Michelle R. Lofwall, Jeanne Manubay, Kevin W. Hatton, Robert A. Whittington, Sharon L. Walsh
Summary: This pilot study compared the IV abuse potential of the mu opioid analgesic oxymorphone with other opioids in individuals with opioid use disorder. The results showed that oxymorphone was more potent in terms of drug liking and respiratory depression compared to hydromorphone and oxycodone. Despite the small sample size, the study detected robust effects of oxymorphone, suggesting its higher abuse potential relative to other opioids.
PSYCHOPHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Lucja Kudla, Ryszard Przewlocki
Summary: The development of G protein-biased opioid agonists shows promise in reducing opioid side effects, but data regarding their addictive properties are inconsistent. More research is needed to determine the potential of these compounds in addressing opioid addiction.
PHARMACOLOGICAL REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Charlene Gadais, Justyna Piekielna-Ciesielska, Jolien De Neve, Charlotte Martin, Anna Janecka, Steven Ballet
Summary: Opioid agonists are commonly used for pain relief, but their side effects can be problematic. Designed multiple ligands (DMLs) offer a promising approach by targeting both opioid and non-opioid pathways involved in pain perception. Newly designed opioid agonist-NK2 or -NK3 antagonists show potential for future opioid hybrid development.
Article
Chemistry, Multidisciplinary
Ranit Lahmy, Harald Hubner, Maximilian F. Schmidt, Daniel Lachmann, Peter Gmeiner, Burkhard Konig
Summary: This study developed photoswitchable ligands that can activate or deactivate clinically relevant mu-opioid receptors using light, allowing for spatial and temporal control of biological activity in various biological investigations. These ligands, modeled after the known agonist fentanyl, can change geometry upon exposure to light and have different photophysical and biochemical properties, which could be valuable in further studying the functional significance of the mu-opioid receptor.
CHEMISTRY-A EUROPEAN JOURNAL
(2022)
Article
Chemistry, Medicinal
Salvatore Pacifico, Valentina Albanese, Davide Illuminati, Erika Marzola, Martina Fabbri, Federica Ferrari, Victor A. D. Holanda, Chiara Sturaro, Davide Malfacini, Chiara Ruzza, Claudio Trapella, Delia Preti, Ettore Lo Cascio, Alessandro Arcovito, Stefano Della Longa, Martina Marangoni, Davide Fattori, Romina Nassini, Girolamo Calo, Remo Guerrini
Summary: In this study, 31 peptides were synthesized and tested for their activity at human recombinant NOP/opioid receptors. The peptide [Dmt(1,5)]N/OFQ(1-13)-NH2 was identified as the most potent dual NOP/mu receptor agonist, with antitussive effects demonstrated in vivo. The molecular mechanisms of peptide binding to the mu receptor were elucidated through experimental and in silico studies.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Alessandro Bonifazi, Francisco O. Battiti, Julie Sanchez, Saheem A. Zaidi, Eric Bow, Mariia Makarova, Jianjing Cao, Anver Basha Shaik, Agnieszka Sulima, Kenner C. Rice, Vsevolod Katritch, Meritxell Canals, J. Robert Lane, Amy Hauck Newman
Summary: Novel drug design aims to retain analgesic effects while reducing addiction risks. Targeting D3R with antagonists/partial agonists can decrease self-administration behaviors in rodents. Bi- or multivalent ligands targeting MOR and D3R show potential in maintaining analgesia with reduced opioid abuse liability.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Pharmacology & Pharmacy
Samuel Singleton, Daniel T. Baptista-Hon, Emily Edelsten, Kirsty S. McCaughey, Ewan Camplisson, Tim G. Hales
Summary: The study revealed that TRV130 and PZM21 exhibit partial agonism in beta-arrestin2 recruitment assay, and reduced mu-receptor availability limits the efficacy of TRV130, also revealing morphine and PZM21 to be partial agonists. Despite limited efficacy in vitro, TRV130 demonstrated potent anti-nociception in wild-type mice without tolerance after daily administration.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Neurosciences
Lihua Sun, Jing Tang, Heidi Liljenback, Aake Honkaniemi, Jenni Virta, Janne Isojarvi, Tomi Karjalainen, Tatu Kantonen, Pirjo Nuutila, Jarmo Hietala, Valtteri Kaasinen, Kari Kalliokoski, Jussi Hirvonen, Harry Scheinin, Semi Helin, Kim Eerola, Eriika Savontaus, Emrah Yatkin, Juha O. Rinne, Anne Roivainen, Lauri Nummenmaa
Summary: The study found that both humans and rats exhibit significant seasonal variations in cerebral MOR availability, primarily associated with seasonal changes in photoperiod. Changes in daylength were shown to influence MOR availability in the brain, impacting behaviors and physiological responses.
JOURNAL OF NEUROSCIENCE
(2021)